(PRWEB UK) 9 April 2013
The Global Cardiovascular Drugs market will decline at a CAGR of 10.47% over the period 2012-2016. According to the report 'Global Cardiovascular Drugs Market 2012-2016.' One of the key factors affecting market growth is the over-dependency of the market on the US. The Global Cardiovascular Drugs market has also been witnessing an increase in R&D activities. However, the increase in healthcare expenditure could be one of the factors that will contribute to the growth of this market.
The 110 page report, the Global Cardiovascular Drugs Market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it covers the Global Cardiovascular Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. The key vendors dominating this market space are AstraZeneca plc, Bristol-Myers Squibb Co., Merck & Co. Inc., Novartis AG, Pfizer Inc., and Sanofi.